Would you consider bone antiresorptive therapy in mCRPC with only 1 lesion per PSMA scan?

This is an important question. One of the best studies to examine this is here:

Francini et al., PMID 34292336 from the abiraterone chemo naive mCRPC multicenter cohort study, in which both survival and SRE free survival were improved with the use of bone resorption inhibitors, especially in men with...